Cover Image

Pre-emptive topical ketorolac tromethamine 0.5% for panretinal photocoagulation

Purpose: To evaluate the efficacy of topical ketorolac tromethamine 0.5% given pre-emptively a day before, for alleviating pain in patients undergoing panretinal photocoagulation (PRP) treatment. Methods: A controlled single-blinded study was conducted on 33 patients with diabetic retinopathy (DR; s...

Full description

Saved in:
Bibliographic Details
Main Authors: Chewa Raja, Joanne Shalini, Singh, Sujaya, Ismail, Fazliana
Format: Article
Published: Mary Ann Liebert 2021
Subjects:
RE Ophthalmology
Online Access:http://eprints.um.edu.my/27127/
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.um.eprints.27127
record_format eprints
spelling my.um.eprints.271272022-05-24T04:25:46Z http://eprints.um.edu.my/27127/ Pre-emptive topical ketorolac tromethamine 0.5% for panretinal photocoagulation Chewa Raja, Joanne Shalini Singh, Sujaya Ismail, Fazliana RE Ophthalmology Purpose: To evaluate the efficacy of topical ketorolac tromethamine 0.5% given pre-emptively a day before, for alleviating pain in patients undergoing panretinal photocoagulation (PRP) treatment. Methods: A controlled single-blinded study was conducted on 33 patients with diabetic retinopathy (DR; severe nonproliferative DR, proliferative DR, or advanced diabetic eye disease) who required PRP treatment in both eyes simultaneously. Each eye of the patients was randomly assigned for ketorolac tromethamine 0.5% eyedrop or placebo. Both eyedrop bottles were randomly labeled. Eyedrops were self-administered by the patients, 4 times a day before the procedure (at 6 am, 12 noon, 6 pm, and 12 midnight) and every 15 min for 1 h (4 times) before the laser. Each patient was subjected to PRP using a Visulas 532s Zeiss device set to spot size 200 mu m, time 0.10 s, and similar to 600 burns in each eye. The pain score was evaluated immediately after treatment in each eye independently with Scott's visual analog scale (VAS) and the McGill Pain Questionnaire (MPQ). Results: VAS pain score in ketorolac-treated eyes (median 3.0, interquatile range IQR] +/- 2.5) was lower than in placebo-treated eyes (median 5.0, IQR +/- 3.0). Total Pain Rate Index score from MPQ was lower in ketorolac-treated eyes (median 3.0, IQR +/- 3.0) than in placebo-treated eyes (median 3.0, IQR +/- 2.5). Both pain score differences are statistically significant with P < 0.05. Conclusion: Topical ketorolac tromethamine 0.5% given pre-emptively a day before is effective in alleviating pain in patients undergoing PRP treatment. Mary Ann Liebert 2021-06-01 Article PeerReviewed Chewa Raja, Joanne Shalini and Singh, Sujaya and Ismail, Fazliana (2021) Pre-emptive topical ketorolac tromethamine 0.5% for panretinal photocoagulation. Journal of Ocular Pharmacology and Therapeutics, 37 (5). pp. 313-317. ISSN 1080-7683, DOI https://doi.org/10.1089/jop.2020.0089 <https://doi.org/10.1089/jop.2020.0089>. 10.1089/jop.2020.0089
institution Universiti Malaya
building UM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Malaya
content_source UM Research Repository
url_provider http://eprints.um.edu.my/
topic RE Ophthalmology
spellingShingle RE Ophthalmology
Chewa Raja, Joanne Shalini
Singh, Sujaya
Ismail, Fazliana
Pre-emptive topical ketorolac tromethamine 0.5% for panretinal photocoagulation
description Purpose: To evaluate the efficacy of topical ketorolac tromethamine 0.5% given pre-emptively a day before, for alleviating pain in patients undergoing panretinal photocoagulation (PRP) treatment. Methods: A controlled single-blinded study was conducted on 33 patients with diabetic retinopathy (DR; severe nonproliferative DR, proliferative DR, or advanced diabetic eye disease) who required PRP treatment in both eyes simultaneously. Each eye of the patients was randomly assigned for ketorolac tromethamine 0.5% eyedrop or placebo. Both eyedrop bottles were randomly labeled. Eyedrops were self-administered by the patients, 4 times a day before the procedure (at 6 am, 12 noon, 6 pm, and 12 midnight) and every 15 min for 1 h (4 times) before the laser. Each patient was subjected to PRP using a Visulas 532s Zeiss device set to spot size 200 mu m, time 0.10 s, and similar to 600 burns in each eye. The pain score was evaluated immediately after treatment in each eye independently with Scott's visual analog scale (VAS) and the McGill Pain Questionnaire (MPQ). Results: VAS pain score in ketorolac-treated eyes (median 3.0, interquatile range IQR] +/- 2.5) was lower than in placebo-treated eyes (median 5.0, IQR +/- 3.0). Total Pain Rate Index score from MPQ was lower in ketorolac-treated eyes (median 3.0, IQR +/- 3.0) than in placebo-treated eyes (median 3.0, IQR +/- 2.5). Both pain score differences are statistically significant with P < 0.05. Conclusion: Topical ketorolac tromethamine 0.5% given pre-emptively a day before is effective in alleviating pain in patients undergoing PRP treatment.
format Article
author Chewa Raja, Joanne Shalini
Singh, Sujaya
Ismail, Fazliana
author_facet Chewa Raja, Joanne Shalini
Singh, Sujaya
Ismail, Fazliana
author_sort Chewa Raja, Joanne Shalini
title Pre-emptive topical ketorolac tromethamine 0.5% for panretinal photocoagulation
title_short Pre-emptive topical ketorolac tromethamine 0.5% for panretinal photocoagulation
title_full Pre-emptive topical ketorolac tromethamine 0.5% for panretinal photocoagulation
title_fullStr Pre-emptive topical ketorolac tromethamine 0.5% for panretinal photocoagulation
title_full_unstemmed Pre-emptive topical ketorolac tromethamine 0.5% for panretinal photocoagulation
title_sort pre-emptive topical ketorolac tromethamine 0.5% for panretinal photocoagulation
publisher Mary Ann Liebert
publishDate 2021
url http://eprints.um.edu.my/27127/
_version_ 1735409502824431616
score 13.211869

Similar Items